HC Wainwright Has Bearish Forecast for MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.17) per share for the quarter, down from their previous forecast of ($0.16). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.46 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $1.98 on Wednesday. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75. The company has a 50-day simple moving average of $1.97 and a 200 day simple moving average of $1.67. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. BML Capital Management LLC increased its position in Milestone Pharmaceuticals by 3.0% in the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after buying an additional 33,196 shares during the last quarter. Atria Investments Inc lifted its holdings in Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the last quarter. PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals during the third quarter worth about $46,000. Finally, Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.